Janssen
Last updated Jun 16, 2026
Evidence Sources
6
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
1
Confidence Coverage
68%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Monoclonal Antibody
- Neurology
- Opioid Overdose
- Antiepileptic
Highest priority development: Regulatory Developments Reshaping Competitive Landscape in Neurology Markets
Portfolio development
Regulatory Developments Reshaping Competitive Landscape in Neurology Markets is an owned Janssen portfolio development in Neurology · Depression.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 68%
Active Signals
14
Investigate Priority
2
Opportunity Score
824
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- EscalateJun 16, 2026Score 68Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Neurology · Alzheimer's Disease
- InvestigateJun 20, 2026Score 63FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Neurology · Opioid Overdose
- MonitorJun 16, 2026Score 60Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection
Neurology · Alzheimer's Disease
Related Assets
Portfolio asset pages with evidence-based assessments.
- Regulatory Developments Reshaping Competitive Landscape in Neurology MarketsModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — LAZCLUZE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TECVAYLI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TREMFYA (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — DARZALEX (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Regulatory Developments Reshaping Competitive Landscape in Neurology MarketsModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- EscalateScore 68Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Neurology · Alzheimer's Disease
- InvestigateScore 63FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Neurology · Opioid Overdose
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Janssen right now?
- Which regulatory precedents should Janssen monitor in Oncology and Monoclonal Antibody?
- How does Regulatory Developments Reshaping Competitive Landscape in Neurology Markets compare to the nearest competitive programs?
- What signals require immediate investigation for Janssen?
- Summarize the strategic implications of recent developments for Janssen.
- Where is the greatest uncertainty in Janssen's competitive positioning?